This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)

This study has been completed.
Information provided by (Responsible Party):
Cardium Therapeutics Identifier:
First received: June 28, 2006
Last updated: February 8, 2012
Last verified: November 2008
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality of life, and cardiovascular outcomes. Two doses will be studied, 2.87 x 10(8) and 2.87 x 10(9) viral particles, to evaluate the dose-response of Ad5FGF-4. Short-term and long-term safety of Ad5FGF-4 will also be evaluated.

Condition Intervention Phase
Angina Pectoris Genetic: Ad5FGF-4 vs. Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina

Resource links provided by NLM:

Further study details as provided by Cardium Therapeutics:

Primary Outcome Measures:
  • Change in treadmill exercise duration from baseline [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Percentage of patients with a =>30% increase in exercise duration compared to baseline [ Time Frame: 4 weeks, 12 weeks and 6 months ]
  • Number of patients with and time to coronary events or all-cause death [ Time Frame: 1 Year ]
  • Change in treadmill exercise duration compared to baseline [ Time Frame: 4 weeks and 6 months ]
  • Change in time to 1 mm ST segment depression during ETT compared to baseline [ Time Frame: 4 weeks, 12 weeks and 6 months ]
  • Change in time to angina onset during ETT compared to baseline [ Time Frame: 4 weeks, 12 weeks and 6 months ]
  • Change in CCS class compared to baseline [ Time Frame: 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months ]
  • Change in weekly frequency of anginal attacks compared to baseline [ Time Frame: 2 weeks, 4 weeks, 8 weeks, 12 weeks and 6 months ]
  • Change in weekly PRN nitroglycerin use compared to baseline [ Time Frame: 2 weeks, 4 weeks, 8 weeks, 12 weeks and 6 months ]
  • Change in quality of life (SAQ, DASI, SF-36, EQ-5D) compared to baseline [ Time Frame: 4 weeks, 12 weeks, 6 months and 12 months ]

Enrollment: 416
Study Start Date: October 2001
Study Completion Date: November 2008
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Genetic: Ad5FGF-4 vs. Placebo
Intracoronary infusion
Experimental: 2
Genetic: Ad5FGF-4 vs. Placebo
Intracoronary infusion
Placebo Comparator: 3
Genetic: Ad5FGF-4 vs. Placebo
Intracoronary infusion


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 30-75 years, male or female, with coronary artery disease
  • Patients over 50 years of age agree to undergo sigmoidoscopy, unless they have undergone such an exam or colonoscopy within the preceding 36 months with negative findings
  • CCS angina Class 2 to 4
  • Stable angina for =>4 weeks despite antianginal drug treatment, and who are able to exercise for at least 3 minutes but no more than 10 minutes on the first qualifying baseline ETT and no more than 12 minutes on the last qualifying baseline ETT using the modified Balke exercise protocol
  • LVEF =>30% by echocardiography, LV angiogram, or a MUGA scan undertaken within the preceding 12 months
  • Classic angina or angina equivalent associated with =>1mm ST segment depression (horizontal or down sloping) at least in the first qualifying ETT. The variability in exercise duration (time to grade 3/4 angina or angina equivalent) does not vary by > 20% in 2 consecutive tests
  • Single, double, or triple vessel coronary artery disease. Patients with 3 vessel disease should have at least 1 proximal major vessel or graft with <70% stenosis
  • Patients who do not require immediate PTCA or CABG surgery
  • Provided written informed consent

Exclusion Criteria:

  • Unstable angina
  • CCS Class 1 angina
  • Patients in whom ECG evidence of exercise induced myocardial ischemia is difficult to detect
  • Intercurrent illness which may interfere with the ability to perform the ETT
  • Untreated life-threatening ventricular arrhythmias
  • Left main coronary artery stenosis =>70%, unless bypassed with a patent graft
  • Coronary artery bypass surgery within the past 6 months, unless those grafts are closed
  • In situ arterial CABG other than the RIMA or LIMA, unless it is 100% occluded
  • Myocardial infarction within the last 8 weeks
  • CHF (NYHA class IV) despite treatment
  • Angioplasty within the previous 6 months
  • Prior transmyocardial laser revascularization
  • Enhanced external counterpulsation (EECP) within 12 weeks prior to study entry
  • Coronary ostial stenosis that precludes adequate catheter engagement in any target vessel
  • Coronary artery to venous communications which bypass the coronary capillary bed
  • Heparin associated thrombocytopenia (HIT)
  • Moderate to severe nonproliferative or proliferative retinopathy from any cause (ETDRS Score > 35), clinically significant macular edema, or previous panretinal photocoagulation therapy
  • History of malignant neoplasms (except superficial basal cell skin carcinoma) within the past 10 years
  • Malignant tumors or abnormal cancer screening tests suspicious for cancer, or patients in whom screening exams indicate possible occult malignancy, unless malignancy has been ruled out
  • Family history of colon cancer in any first-degree relative, unless the patient has undergone a colonoscopy within the past 12 months with negative findings
  • Elevated PSA level (unless prostate cancer has been excluded)
  • HIV positive
  • Hepatic disease or those who are positive for hepatitis B or C, or whose SGPT is > 2 times the upper limit of normal range, or whose serum bilirubin is > 2 mg/dL.
  • Proteinuria => 2+ unless all other renal parameters are within normal limits.
  • Creatinine clearance < 45 ml/min
  • Platelet count less than 130 x 10(3)/microL
  • WBC count less than 3.0 x 10(3)/microL
  • Patients who are known to be immunosuppressed and/or are receiving chronic immunosuppressive therapy
  • Female patients of childbearing potential. Male patients who do not agree to use birth control (condom) for a period of 8 weeks following study product administration
  • Investigational drug therapy within 30 days of treatment
  • Patients who have received any gene therapy product or angiogenic growth factor protein product
  • Underlying disease(s) other than CAD resulting in a life expectancy of less than 1 year
  • Any clinical abnormality or social circumstance that puts successful completion of the trial in doubt
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346437

Sponsors and Collaborators
Cardium Therapeutics
Study Director: Paul Foster, MD Cardium Therapeutics, 12255 El Camino Real #250, San Diego, CA 92130, (858) 436-1000
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cardium Therapeutics Identifier: NCT00346437     History of Changes
Other Study ID Numbers: 304386
Study First Received: June 28, 2006
Last Updated: February 8, 2012

Keywords provided by Cardium Therapeutics:
growth factor
myocardial ischemia

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Signs and Symptoms processed this record on September 19, 2017